# Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT04502706** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 9 (actual)

## Conditions studied

- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** GS-0189
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04502706
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-17
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor's decision to discontinue development of this molecule
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502706, "Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04502706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*